Go-CHOP in de Novo Intestinal T-cell Lymphoma Patients
Status:
NOT_YET_RECRUITING
Trial end date:
2027-12-04
Target enrollment:
Participant gender:
Summary
The goal of this observational study is to evaluate the safety and efficacy of Go-CHOP (Golidocitinib plus Cyclophosphamide, Hydroxydoxorubicin, Oncovin and Prednisone) in de novo intestinal T-cell lymphoma patients, The aim is to evaluate the complete response rate (CRR). Participants will receive Go-CHOP for 6 cycles every 21 days followed by either maintenance therapy or ASCT.